Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80224 | 0.91 | ALDH1A1 (0.36) | CYP11B1ALDH1A1HPGDTSHRMAPK1 | |
| SCHEMBL80800 | 0.87 | KMT2A (0.36) | ALDH1A1KMT2A | |
| SCHEMBL80236 | 0.86 | CYP11B1 (0.39) | CYP11B1ALDH1A1HPGDTSHRMAPK1 | |
| SCHEMBL82037 | 0.86 | KMT2A (0.35) | ALDH1A1KMT2A | |
| SCHEMBL10036758 | 0.84 | CYP11B1 (0.38) | CYP11B1ALDH1A1HPGDTSHRMAPK1 | |
| SCHEMBL81481 | 0.84 | KMT2A (0.32) | KMT2A | |
| SCHEMBL80250 | 0.84 | MAOB (0.33) | ALDH1A1KMT2A | |
| SCHEMBL10036759 | 0.83 | KMT2A (0.34) | ALDH1A1HPGDMAPK1HSD17B10KMT2A | |
| SCHEMBL81022 | 0.83 | PDK2 (0.36) | CYP11B1ALDH1A1HPGDTSHRMAPK1 | |
| SCHEMBL80242 | 0.82 | PDK2 (0.33) | ALDH1A1HPGDMAPK1HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129899-B1 | Azafluorene derivative and organic light-emitting device using the derivative | CANON KABUSHIKI KAISHA (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129899-B1 | Azafluorene derivative and organic light-emitting device using the derivative | CANON KABUSHIKI KAISHA (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20120049176-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20120049176-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2012-03-01 | — | — | US | disclosed |
| US-8110685-B2 | Efficient, durable electron transport layers; low driving voltage; simple, low cost production | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110685-B2 | Efficient, durable electron transport layers; low driving voltage; simple, low cost production | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20080154040-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2008-06-26 | — | — | US | disclosed |
| US-20080154040-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080154040-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | AZI2, CYP1A2, CYP2C19 | CYP11B1 761/4885ALDH1A1 21/4885HPGD 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.